Remission with carbimazole therapy & assessment of T4 suppression test as an index of relapse in patients with Graves' disease in India

Indian Journal of Medical Research

Volumn 103, Issue MAY, 1996, Pages 272-277

  Goswami, R ^a   Bal, C S ^a   Gupta, N ^a   Kochupillai, N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Carbimazole; Graves' disease; Remission; T4 suppression test

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; PROTIRELIN; THYROXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; INDIA; MALE; RELAPSE; REMISSION;

ADULT; CARBIMAZOLE; FEMALE; GRAVES DISEASE; HUMANS; MALE; RECURRENCE; REMISSION INDUCTION; THYROID FUNCTION TESTS; THYROXINE;

EID: 0029945796     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Astwood EB. Treatment of hyperthyroidism with thiourea and thiouracil. JAMA 1943; 122: 78-81.
2. Totterman TH, Karlsson FA. Bengtsson M. Mendel-Hartvig I. Induction of circulating activated suppressor-like T cell by methimazole therapy for Graves' disease. N Engl J Med 1987; 316: 15-22.
3. Volpe R, Karlsson A, Jansson R, Dahlberg PA. Evidence that antithyroid drugs induce remissions in Graves' disease by modulating thyroid cellular activity. Clin. Endocrinol (Oxf) 1986; 25: 453-62.
4. Cooper DS. Treatment of thyrotoxicosis. In: Braverman LE, Utiger RD, editors. Werner's and Ingbar's the thyroid-a fundamental and clinical text. Philadelphia: Lippincott. 1991 : 887-916.
5. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y et al. Antithyroid drugs and Graves' disease. A prospective randomised evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70: 675-9.
6. Laurberg P, Buchholtz-Hansen PE, Iversen E, Eskjaer Jansen S, Wecke J, Goiter size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Copenh) 1986; 111: 39-43.
7. DeBruin TW, Bokh JH, Bussemaker JK, Stijnen T, Schreuder GM, DeVries RRP. Graves' disease: immunological and immunogenetic indicators of relapse. Br Med J 1988; 296: 1292-5.
8. Solomon BL, Evaul JE, Burman KD, Wartofsky L. Remission rates with antithyroid drug therapy: continuing influence of iodine intake? Ann Intern Med 1987; 107: 510-2.
9. Schleusener H, Schwander J, Fischer C. Holle R, Holl G, Badenhoop K et at. Prospective multicenteric study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh) 1989; 120: 689-701.
10. Hamburger JI. Is long term antithyroid drug therapy for Graves' disease cost effective? In: Hamburger JI, Miller JM, editors. Controversies in clinical throidology. New York: Springer-Verlag, 1981: 138-9.
11. Ramaldini JH, Bromberg N, Werner RS, Tanaka I.M. Rodrigues HF, Werner MC. et al. Comparison of the effects of the high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983; 57: 553-70.
12. Hennemann G, Krenning EP, Sankaranarayanan K. Place of radiactive iodine in the treatment of thyrotoxicosis. Lancet 1986; 7: 1369-72.
13. Ramalingaswami V. Kochupillia N. Health significance of iodine deficiency. In : Kochupillai N, Karmakar MG. Ramalingaswami V. editors. Iodine nutrition, thyroxine and brain development. New Delhi: TataMcGraw-Hill, 1986: 1- 17.
14. Crooks J. Murray I PC, Wayne EJ. Statistical methods applied to the clinical diagnosis of thyrotoxicosis. QJM 1959; 28: 211-34.
15. Volpe R. Graves' disease. In : Braverman LE, Utiger RD, editors. Werner's and Ingbar's the thyroid-a fundamental and clinical text. Philadelphia : Lippincott. 1991: 887-916.
16. WHO/UNICEF/ICCIDD. Indicators for assessing iodine deficiency disorders and their Control programmes. WHO/ Nut/93. 1.
17. Barker SB. Humphery MJ. Soley MH. The clinical determination of protein-bound urinary iodine. J Clin Invest 1951; 30: 55-62.
18. 125I containing acylating agent. Biochem J 1973; 133 : 529-39.
19. Goldman L. Quantitative aspects of clinical reasoning. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, editors. Harrison's principles of internal medicine. New York: McGraw-Hill 1994: 43-8.
20. 131 uptake in patients wiht Graves' diseae compared to T3 suppression test. Endoctinol Jpn 1984; 31: 263-70.
21. Cavalieri RR. In vivo isotopic test and imaging. In: Braverman LE, Utiger RD, editors. Werner's nad Ingbar's the thyroid a fundamental and clinical text. Philadelphia: Lippincott. 1991 : 437-45.
22. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A, Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334: 220-4.
23. Taurog A, Dorris ML. A re-examination of the proposed inactivation of thyroid peroxidase in the rat thyroid by propylhiouracil. Endocrinology 1989; 124: 3038-42.
24. Larsen PR, Iangbar SH. The thyroid gland. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology. Philadelphia: Saunders, 1992: 358-487.
25. Sugrue D, McEvoy M, Feely J, Drury MI. Hyperthyroidism in the land of Graves': result of treatment by surgery, radioiodine and carbimazole in 837 cases. Q J Med 1980; 49: 51-61.
26. Jorde R. Ytre-Arne & Stomer J, Sundsfjord J. Short-term treatment of Graves' disease in high versus low doses. J Intern Med 1995; 238: 161-5.
27. Holm LE, Alinder I. Relapses after thionamide therapy for Graves' disease, Acta Med Scand 1982; 277: 489-92.
28. Azizi F. Environmental iodine affects the response to methimazole in patients with diffuse toxic goiter. J Clin Endocrinol Metab 1985; 61: 374-77.